Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer

NCT02531425 is registered in ClinicalTrials.gov with OncoSec Medical Incorporated as lead sponsor.

NCT NCT02531425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02531425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer
Lead sponsor
OncoSec Medical Incorporated
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2015
Completion date
July 31, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

er-negative pr-negative her2-negative breast cancer